.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing glycemic control remains a significant challenge for many individuals with advanced type 2 diabetes. While injectable GLP-1 receptor agonists are highly effective, many patients prefer oral alternatives. Orforglipron for Type 2 Diabetes represents a major shift in treatment, as it is a nonpeptide, small-molecule agonist that can be taken once daily without the strict fasting requirements associated with some other oral agents. The recently published ACHIEVE-5 trial investigated whether adding orforglipron to titrated insulin glargine could further optimize blood glucose levels and metabolic health.
The phase 3 ACHIEVE-5 study enrolled 546 adults who were already using insulin glargine but had inadequate glycemic control. Researchers randomized participants to receive either a placebo or one of three daily dosages of orforglipron: 3 mg, 12 mg, or 36 mg. After 40 weeks, the results were statistically significant. Specifically, participants taking orforglipron achieved mean HbA1c reductions between -1.58% and -1.88%, compared to just -0.79% in the placebo group. Furthermore, a substantially higher percentage of those in the orforglipron group reached the target HbA1c of less than 7.0%.
Beyond glycemic control, the trial highlighted impressive weight loss outcomes. Participants receiving the 36-mg dose experienced a mean body weight change of -8.41%, whereas the placebo group saw a slight weight increase of 0.60%. This weight-neutral or weight-reducing effect is particularly beneficial for patients on insulin therapy, which is often associated with weight gain. Additionally, orforglipron demonstrated a manageable safety profile. Although gastrointestinal side effects like nausea and diarrhea were more common in the orforglipron arms, most cases were mild to moderate. These events typically occurred during the initial dose-escalation phase and decreased over time.
Hypoglycemia is a major concern when adding new agents to insulin. However, the ACHIEVE-5 trial found that rates of clinically significant hypoglycemia (level 2 or 3) were generally similar between the orforglipron and placebo groups. This suggests that orforglipron can be safely integrated into complex insulin regimens. Consequently, this oral option may provide a viable alternative for patients who have reached their limit with injectable therapies but still require additional metabolic support.
Orforglipron is a nonpeptide, small-molecule agonist. Unlike peptide-based GLP-1s like semaglutide, orforglipron is not easily degraded by stomach acid and does not require complex oral delivery technologies or strict fasting before administration.
The most common side effects were gastrointestinal, including nausea, vomiting, and diarrhea. These symptoms were dose-dependent and typically occurred during the early stages of treatment titration.
Yes. In the ACHIEVE-5 trial, the highest dose of orforglipron led to an average weight loss of approximately 8.4% over 40 weeks, which is a significant benefit for patients with type 2 diabetes and obesity.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Giorgino F et al. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. JAMA. 2026 Jun 07. doi: 10.1001/jama.2026.9512. PMID: 42251769.
Frias JP et al. Orforglipron for the Treatment of Type 2 Diabetes. New England Journal of Medicine. 2023;389(10):896-907.
Wharton S et al. Daily Oral Orforglipron for Adults with Obesity. New England Journal of Medicine. 2023;389(10):877-888.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ACHIEVE-5 trial demonstrates that orforglipron significantly reduces HbA1c and body weight in type 2 diabetes patients using insulin glargine....
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
